Gallium nitrate (DrugBank: Gallium nitrate, Nitrate)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
58 | Hypertrophic cardiomyopathy | 0 |
113 | Muscular dystrophy | 0 |
299 | Cystic fibrosis | 3 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04294043 (ClinicalTrials.gov) | May 1, 2020 | 1/3/2020 | IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) | A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients With Cystic Fibrosis (CF) Who Are Colonized With Nontuberculous Mycobacteria (NTM) (The ABATE Study) | Nontuberculous Mycobacterium Infection | Drug: Gallium nitrate | Chris Goss | Cystic Fibrosis Foundation | Not yet recruiting | 18 Years | N/A | All | 40 | Phase 1 | United States |
2 | NCT02354859 (ClinicalTrials.gov) | March 2016 | 30/7/2014 | A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study) | A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study) | Cystic Fibrosis | Drug: Gallium nitrate;Drug: Normal Saline | University of Washington | Cystic Fibrosis Foundation | Completed | 18 Years | N/A | All | 119 | Phase 2 | United States |
3 | NCT01093521 (ClinicalTrials.gov) | April 2010 | 24/3/2010 | A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients | A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients | Cystic Fibrosis | Drug: 100 mg/m2 dose;Drug: 200 mg/m2 dose | University of Washington | Cystic Fibrosis Foundation | Completed | 18 Years | 55 Years | All | 20 | Phase 1 | United States |